Elevation of serum CXCL16 level correlates well with atherosclerotic ischemic stroke

Archives of Medical Science

Volumn 10, Issue 1, 2014, Pages 47-52

  Ma, Aijun ^a   Pan, Xudong ^a   Xing, Yubo ^b   Wu, Mei ^c   Wang, Yuan ^a   Ma, Cuiling ^a  

^a QINGDAO UNIVERSITY   (China)

^b Department of Neurology   (China)

^c QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Atherosclerosis; Chemokine; CXCL16; Inflammation; Ischemic stroke

Indexed keywords

C REACTIVE PROTEIN; CXCL16 CHEMOKINE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC ISCHEMIC STROKE; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; VERY ELDERLY; YOUNG ADULT;

EID: 84900669625     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2013.39200     Document Type: Article

References (28)

1. Chalela JA, Merino JG, Warach S. Update on stroke. Curr Opin Neurol 2004; 17: 447-51.
2. Zhao D, Liu J, Wang W, et al. Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project. Stroke 2008; 39: 1668-74.
3. Flossmann E, Schulz UG, Rothwell PM. Potential confounding by intermediate phenotypes in studies of the genetics of ischaemic stroke. Cerebrovasc Dis 2005; 19: 1-10.
4. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-26.
6. Sheikine Y, Sirsjo A. CXCL16/SR-PSOX: a friend or a foe in atherosclerosis? Atherosclerosis 2008; 197: 487-95.
7. Shimaoka T, Kume N, Minami M, et al. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 2000; 275: 40663-6.
8. Matloubian M, David A, Engel S, Ryan JE, Cyster JG. A transmembrane CXC chemokine is a ligand for HIVcoreceptor Bonzo. Nat Immunol 2000; 1: 298-304.
9. Minami M, Kume N, Shimaoka T, et al. Expression of scavenger receptor for phosphatidylserine and oxidized lipoprotein (SR-PSOX) in human atheroma. Ann N Y Acad Sci 2001; 947: 373-6.
10. Smith C, Halvorsen B, Otterdal K, et al. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. Cardiovasc Res 2008; 79: 195-203.
11. Wuttge DM, Zhou X, Sheikine Y, et al. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004; 24: 750-5.
12. Minami M, Kume N, Shimaoka T, et al. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001; 21: 1796-800.
13. Aslanian AM, Charo IF. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 2006; 114: 583-90.
14. Abel S, Hundhausen C, Mentlein R, et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 2004; 172: 6362-72.
15. Sheikine Y, Bang CS, Nilsson L, et al. Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease. Atherosclerosis 2006; 188: 462-6.
16. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991; 325: 445-53.
17. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
18. Waje-Andreassen U, Kråkenes J, Ulvestad E, et al. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand 2005; 111: 360-5.
19. Idicula TT, Brogger J, Naess H, Waje-Andreassen U, Thomassen L. Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the 'Bergen stroke study'. BMC Neurol 2009; 9: 18.
20. Di Napoli M, Singh P. Is plasma fibrinogen useful in evaluating ischemic stroke patients: why, how, and when? Stroke 2009; 40: 1549-52.
21. Yu DQ, Lin SG, Chen JY, et al. Effect of atorvastatin therapy on borderline vulnerable lesions in patients with acute coronary syndrome. Arch Med Sci 2011; 7: 433-9.
22. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 2003; 170: 1136-40.
23. Wågsater D, Olofsson PS, Norgren L, Stenberg B, Sirsjo A. The chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferon gamma. Biochem Biophys Res Commun 2004; 325: 1187-93.
24. Sun Y, Chang Z, Zhang S. Increased serum CXCL16 level is a marker for acute coronary syndromes. Arch Med Res 2008; 39: 332-7.
25. Yi GW, Zeng QT. Circulating CXCL16 is related to the severity of coronary artery stenosis. Arch Med Res 2008; 39: 531-5.
26. Wang KD, Liu ZZ, Wang RM, et al. Chemokine CXC Ligand 16 serum concentration but not A181V genotype is associated with atherosclerotic stroke. Clin Chim Acta 2010; 411: 1447-51.
27. Zhuge X, Murayama T, Arai H, et al. CXCL16 is a novel angiogenic factor for human umbilical vein endothelial cells. Biochem Biophys Res Commun 2005; 331: 1295-300.
28. Russell DA, Abbott CR, Gough MJ. Vascular endothelial growth factor is associated with histological instability of carotid plaques. Br J Surg 2008; 95: 576-81.